DE60335997D1 - Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus - Google Patents
Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcusInfo
- Publication number
- DE60335997D1 DE60335997D1 DE60335997T DE60335997T DE60335997D1 DE 60335997 D1 DE60335997 D1 DE 60335997D1 DE 60335997 T DE60335997 T DE 60335997T DE 60335997 T DE60335997 T DE 60335997T DE 60335997 D1 DE60335997 D1 DE 60335997D1
- Authority
- DE
- Germany
- Prior art keywords
- ulcus
- treating diabetic
- lactoferrin compositions
- lactoferrin
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41098102P | 2002-09-16 | 2002-09-16 | |
PCT/US2003/029069 WO2004024180A1 (en) | 2002-09-16 | 2003-09-16 | Lactoferrin compositions and methods of wound treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60335997D1 true DE60335997D1 (de) | 2011-03-24 |
Family
ID=31994228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60335997T Expired - Lifetime DE60335997D1 (de) | 2002-09-16 | 2003-09-16 | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
Country Status (12)
Country | Link |
---|---|
US (3) | US7524814B2 (de) |
EP (2) | EP1545587B1 (de) |
JP (1) | JP4516844B2 (de) |
CN (1) | CN1694720A (de) |
AT (1) | ATE497778T1 (de) |
AU (2) | AU2003270690B2 (de) |
CA (1) | CA2499014A1 (de) |
DE (1) | DE60335997D1 (de) |
DK (2) | DK1545587T3 (de) |
ES (1) | ES2358645T3 (de) |
SI (2) | SI1545587T1 (de) |
WO (1) | WO2004024180A1 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
AU2003273182B8 (en) | 2002-05-10 | 2009-05-07 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
EP1545587B1 (de) * | 2002-09-16 | 2011-02-09 | Agennix Incorporated | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
CA2508912A1 (en) * | 2002-12-06 | 2004-06-24 | Agennix Incorporated | Oral lactoferrin in the treatment of sepsis |
AU2003296447A1 (en) | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
AU2004289170B2 (en) * | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
CA2577777A1 (en) * | 2004-08-20 | 2006-03-02 | Smithkline Beecham Corporation | Methods of healing wounds by administering human il-18 |
WO2006047744A2 (en) | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
US8263105B2 (en) * | 2004-12-01 | 2012-09-11 | Tyco Healthcare Group Lp | Biomaterial drug delivery and surface modification compositions |
ITRM20040638A1 (it) | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | Gel piastrinico semisintetico e metodo per la sua preparazione. |
US20060240116A1 (en) * | 2005-04-22 | 2006-10-26 | David Jolley | Bioactive factors in wound healing topical compositions and methods |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
WO2007022537A2 (en) * | 2005-08-19 | 2007-02-22 | Agennix Incorporated | Use of lactoferrin as a chemokine and a chemotactic modulator |
US20070059300A1 (en) * | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
WO2007061942A2 (en) | 2005-11-18 | 2007-05-31 | Glanbia Nutritionals (Ireland) Ltd. | Compositions for disrupting and inhibiting reconstitution of wound biofilm |
US20070179084A1 (en) * | 2006-01-30 | 2007-08-02 | Nation Chiao Tung University | Process for reducing the concentration of blood glucose in a diabetic patient |
EP1815877B1 (de) * | 2006-02-02 | 2009-11-25 | Euro-Celtique S.A. | Hydrogel für Wundbehandlung |
EP1993592A4 (de) * | 2006-02-21 | 2011-11-16 | Ventria Bioscience | Zusammensetzungen mit lactoferrin und verfahren zu ihrer verwendung zur anregung des wachstums von hautzellen |
EP2081588A1 (de) * | 2006-07-03 | 2009-07-29 | Jean-Paul Perraudin | Antimikrobielle zusammensetzung und ihre verwendungen |
GB0616580D0 (en) * | 2006-08-21 | 2006-09-27 | Novathera Ltd | Composite material |
AU2007294808A1 (en) | 2006-09-13 | 2008-03-20 | Southeastern Medical Technologies, Llc | Methods and compositions for sealing and adhering biological tissues and medical uses thereof |
US10143694B2 (en) * | 2006-10-27 | 2018-12-04 | Matthew H. Kopacki | Advanced formulations and therapies for treating hard-to-heal wounds |
PE20090190A1 (es) * | 2007-03-23 | 2009-03-22 | Smithkline Beecham Corp | Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18 |
US20110021431A1 (en) * | 2008-04-01 | 2011-01-27 | Jones Curtis E | Methods And Compositions For Medical Articles Produced From Proteinaceous Compounds |
EP2141242A1 (de) | 2008-07-04 | 2010-01-06 | Universität des Saarlandes | Synthetische Wegenzyme zur Herstellung von Argyrinen |
US8614189B2 (en) * | 2008-09-24 | 2013-12-24 | University Of Connecticut | Carbon nanotube composite scaffolds for bone tissue engineering |
US20110015587A1 (en) * | 2009-07-14 | 2011-01-20 | Tumey David M | Irrigation Device and Method Using Same |
JP2011020973A (ja) * | 2009-07-17 | 2011-02-03 | Nrl Pharma Inc | 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料 |
ES2569922T3 (es) * | 2009-11-25 | 2016-05-13 | Nestec S.A. | Composiciones nutritivas, que incluyen un componente de alto contenido en proteínas y nucleótidos exógenos |
US8545927B2 (en) | 2010-05-10 | 2013-10-01 | University Of Connecticut | Lactoferrin-based biomaterials for tissue regeneration and drug delivery |
AU2011274244A1 (en) * | 2010-07-01 | 2013-01-10 | Brien Holden Vision Institute | Lactoferrin sequences, compositions and methods of corneal wound treatment |
US10279007B2 (en) | 2010-11-15 | 2019-05-07 | Oxygenetix Institute, Inc. | Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs |
US20120171231A1 (en) * | 2010-12-29 | 2012-07-05 | Anja Wittke | Use of nutritional compositions including lactoferrin in stimulating immune cells |
JP5993308B2 (ja) | 2011-01-26 | 2016-09-14 | 雪印メグミルク株式会社 | 感覚改善剤 |
US10064858B2 (en) | 2011-01-31 | 2018-09-04 | The United States Of America, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
WO2013032745A1 (en) * | 2011-08-31 | 2013-03-07 | Kci Licensing, Inc. | Reduced-pressure treatment and debridement systems and methods |
CN104884079B (zh) * | 2012-11-14 | 2021-02-12 | 史密夫和内修公司 | 稳定的嗜热菌蛋白酶水凝胶 |
JP6275955B2 (ja) * | 2013-04-25 | 2018-02-07 | 松尾 敏郎 | 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法 |
CZ308554B6 (cs) * | 2013-10-21 | 2020-11-25 | Univerzita Tomáše Bati ve Zlíně | Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků |
KR20170086019A (ko) | 2014-09-24 | 2017-07-25 | 이스티튜토 프로필라티코 이 파르마씨유티코 칸디올리 & 씨. 에스.피.에이. | 감염증 및 염증의 예방 및/또는 치료에 유용한 조성물 |
RU2658707C1 (ru) * | 2016-12-28 | 2018-06-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ восстановления кожного покрова |
US20200024329A1 (en) * | 2018-07-17 | 2020-01-23 | Bradley G. Thompson | Methods for regulating endogenous production of lactoferrin and sub-peptides thereof |
CN112533590A (zh) * | 2018-07-31 | 2021-03-19 | 雷莫内克斯生物制药有限公司 | 用于使伤口愈合的药物组合物 |
WO2020121179A1 (en) * | 2018-12-11 | 2020-06-18 | Universita' Degli Studi Di Salerno | Composition for the treatment of skin lesions |
CN110075054A (zh) * | 2019-06-06 | 2019-08-02 | 山东天源人乳库科技发展有限公司 | 一种来源于人乳的人源性生长因子修复制剂及其制备方法 |
BE1027357B1 (nl) * | 2019-06-12 | 2021-01-18 | Vanlommel Maria Kristel | Voedingssupplement voor versnelde genezing |
CN110680949B (zh) * | 2019-10-18 | 2021-06-29 | 中山大学 | 一种基于母乳的创伤敷料的制备方法和应用 |
WO2023028498A1 (en) * | 2021-08-23 | 2023-03-02 | Lactea Therapeutics Llc | Lactoferrin compositions and methods of use |
CN113576938B (zh) * | 2021-08-26 | 2022-07-08 | 广东丸美生物技术股份有限公司 | 一种口腔护理组合物及其应用 |
CN116421775A (zh) * | 2023-04-21 | 2023-07-14 | 青岛优瑞达生物科技有限公司 | 一种乳铁蛋白凝胶敷料、制备方法和应用 |
CN116251224B (zh) * | 2023-05-16 | 2023-09-12 | 江苏正大天创生物工程有限公司 | 一种乳铁蛋白凝胶敷料及其应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4788488A (en) * | 1986-10-14 | 1988-11-29 | Drexelbrook Controls, Inc. | Continuous condition sensing system |
US4783488A (en) * | 1987-01-31 | 1988-11-08 | Bausch & Lomb Incorporated | Contact lens wetting solution |
US4977137B1 (en) * | 1987-06-03 | 1994-06-28 | Baylor College Medicine | Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract |
US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
US5284760A (en) | 1989-04-03 | 1994-02-08 | Feinstone Stephen M | Techniques for producing site-directed mutagenesis of cloned DNA |
US5849881A (en) * | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
US5571697A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
US5571691A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
US6100054A (en) | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
IL94183A (en) * | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
US5198419A (en) * | 1989-12-08 | 1993-03-30 | Immuno Japan Inc. | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria |
JP3395904B2 (ja) * | 1990-01-12 | 2003-04-14 | ニューヨーク ソサイエティ フォー ザ リリーフ オヴ ザ ラプチャード アンド クリップルド,メインテイニング ザ ホスピタル フォー スペシャル サージェリー | 創傷治癒および組織修復を高める方法 |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US6066469A (en) | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
GB2248842A (en) | 1990-10-16 | 1992-04-22 | American Cyanamid Co | Film-forming polymer compositions |
WO1992008477A1 (en) * | 1990-11-13 | 1992-05-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for corneal lesion |
EP0590060B1 (de) | 1991-06-21 | 1997-09-17 | University Of Cincinnati | Oral verabreichbare therapeutische proteine und herstellungsverfahren |
JP3398957B2 (ja) | 1991-12-24 | 2003-04-21 | ザ・プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | Dnaの特定部位の突然変異誘発 |
DE69322896T2 (de) * | 1992-03-02 | 1999-05-27 | Japan Immuno Inc | Verwendung von Proteinen der Transferrin/Lactoferrin-Familie zur Stimulation des Immunsystems |
DE4208552A1 (de) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
NL9220019A (nl) * | 1992-04-10 | 1994-04-05 | Vnii Med Polimerov | Farmaceutische samenstelling. |
ZA932568B (en) | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
US5389514A (en) | 1992-08-28 | 1995-02-14 | Fox Chase Cancer Center | Method for specifically altering the nucleotide sequence of RNA |
US5358706A (en) | 1992-09-30 | 1994-10-25 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
JPH07196529A (ja) * | 1993-12-29 | 1995-08-01 | Morinaga Milk Ind Co Ltd | 創傷治癒剤、化粧料および養毛剤 |
EP1142484A2 (de) | 1994-02-16 | 2001-10-10 | Pharming Intellectual Property BV | Isolierung von Lactoferrin aus Milch |
JP3746081B2 (ja) | 1994-02-24 | 2006-02-15 | 森永乳業株式会社 | 動物皮膚病治療剤 |
US5827874A (en) * | 1995-05-05 | 1998-10-27 | Meyer; Hans | Methods of treating pain and inflammation with proline |
US20020016289A1 (en) * | 1995-06-01 | 2002-02-07 | Orla M. Conneely | Methods for treatment and prevention of helicobacter pylori infection using lactoferrin |
US5834424A (en) * | 1995-07-12 | 1998-11-10 | Gambit International Limited | Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus |
US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
GB2321191B (en) * | 1997-01-17 | 2000-09-27 | Johnson & Johnson Medical | Peptides for use in wound treatment |
EP1017407A2 (de) | 1997-02-03 | 2000-07-12 | Pharming Intellectual Property BV | Nützliche eigenschaften von humanem lactoferrin und varianten davon |
CN1262625A (zh) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | 乳铁蛋白在治疗过敏原诱发疾病中的应用 |
JP3856908B2 (ja) * | 1997-06-06 | 2006-12-13 | 田辺製薬株式会社 | 褥瘡及び/又は創傷治療剤 |
US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
RU2165769C1 (ru) | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
ES2384099T3 (es) | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
AU2003273182B8 (en) * | 2002-05-10 | 2009-05-07 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
EP1545587B1 (de) * | 2002-09-16 | 2011-02-09 | Agennix Incorporated | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus |
US7026295B2 (en) | 2002-12-04 | 2006-04-11 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
CA2508912A1 (en) | 2002-12-06 | 2004-06-24 | Agennix Incorporated | Oral lactoferrin in the treatment of sepsis |
AU2003296447A1 (en) | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
US7323443B2 (en) * | 2002-12-12 | 2008-01-29 | Agennix Inc. | Lactoferrin in the reduction of pain |
WO2004103285A2 (en) | 2003-05-14 | 2004-12-02 | Agennix Incorporated | Lactoferrin in the treatment of diabetes mellitus |
AU2004289170B2 (en) | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
-
2003
- 2003-09-16 EP EP03752398A patent/EP1545587B1/de not_active Expired - Lifetime
- 2003-09-16 DK DK03752398.2T patent/DK1545587T3/da active
- 2003-09-16 JP JP2004536558A patent/JP4516844B2/ja not_active Expired - Fee Related
- 2003-09-16 DE DE60335997T patent/DE60335997D1/de not_active Expired - Lifetime
- 2003-09-16 ES ES03752398T patent/ES2358645T3/es not_active Expired - Lifetime
- 2003-09-16 US US10/663,258 patent/US7524814B2/en not_active Expired - Fee Related
- 2003-09-16 CA CA002499014A patent/CA2499014A1/en not_active Abandoned
- 2003-09-16 WO PCT/US2003/029069 patent/WO2004024180A1/en active Application Filing
- 2003-09-16 SI SI200331990T patent/SI1545587T1/sl unknown
- 2003-09-16 DK DK10014943.4T patent/DK2298338T3/da active
- 2003-09-16 CN CNA038250683A patent/CN1694720A/zh active Pending
- 2003-09-16 SI SI200332199T patent/SI2298338T1/sl unknown
- 2003-09-16 AU AU2003270690A patent/AU2003270690B2/en not_active Ceased
- 2003-09-16 AT AT03752398T patent/ATE497778T1/de not_active IP Right Cessation
- 2003-09-16 EP EP10014943A patent/EP2298338B1/de not_active Expired - Lifetime
-
2009
- 2009-03-12 US US12/403,250 patent/US8030272B2/en not_active Expired - Fee Related
- 2009-10-13 AU AU2009225309A patent/AU2009225309B2/en not_active Expired - Fee Related
-
2011
- 2011-09-08 US US13/227,871 patent/US8247373B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2004024180A1 (en) | 2004-03-25 |
DK1545587T3 (da) | 2011-05-09 |
US20090253627A1 (en) | 2009-10-08 |
DK2298338T3 (da) | 2012-09-24 |
EP2298338A1 (de) | 2011-03-23 |
EP1545587A1 (de) | 2005-06-29 |
SI2298338T1 (sl) | 2012-11-30 |
CA2499014A1 (en) | 2004-03-25 |
CN1694720A (zh) | 2005-11-09 |
EP2298338B1 (de) | 2012-08-22 |
ATE497778T1 (de) | 2011-02-15 |
US8030272B2 (en) | 2011-10-04 |
EP1545587A4 (de) | 2009-06-17 |
AU2003270690B2 (en) | 2009-07-30 |
AU2009225309A1 (en) | 2009-11-05 |
JP4516844B2 (ja) | 2010-08-04 |
US7524814B2 (en) | 2009-04-28 |
US20040142037A1 (en) | 2004-07-22 |
US8247373B2 (en) | 2012-08-21 |
JP2006503044A (ja) | 2006-01-26 |
EP1545587B1 (de) | 2011-02-09 |
AU2009225309B2 (en) | 2012-06-14 |
ES2358645T3 (es) | 2011-05-12 |
SI1545587T1 (sl) | 2011-06-30 |
US20120010150A1 (en) | 2012-01-12 |
AU2003270690A1 (en) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60335997D1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
ATE302017T1 (de) | Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden | |
ATE427956T1 (de) | Ckrox-peptide und ihre analoge zur behandlung von hautalterung | |
ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
ATE138567T1 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
DE50209139D1 (de) | Zweikomponenten-Mittel mit zeitlichem pH-Gradienten und Verfahren zur Behandlung von Haaren | |
DE602005016198D1 (de) | Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden | |
DE60313434D1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
ATE287713T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
ATE275580T1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
DE502004011486D1 (de) | Antioxidationsmittel für organisches material und verfahren zur behandlung desselben | |
DE69820911D1 (de) | Verwendung einer Verbindung zur Herstellung eines Medikaments zur Behandlung von Alopecia oder zur Förderung des Haarwuchses bei Tieren | |
DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten |